# Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure

> **NCT01667614** · PHASE2 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 136 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Diabetic Nephropathy
- Essential Hypertension

## Interventions

- **DRUG:** spironolacone 25 mg tablets added to losartan

## Key facts

- **NCT ID:** NCT01667614
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-07
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2012-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01667614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01667614, "Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01667614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*